Internal Medicine Alert (Vol. 38, No. 18) - September 30, 2016

Read the Disclosure Information Below, then click “Continue” to begin testing.

Release date: September 2016

Valid through: September 2019

Target Audience

This CME activity is intended for the internist/family physician.

Subjects

  • Influence of Sacubitril/Valsartan on 30-day Readmission After Heart Failure Hospitalization
  • Integrative Treatment for Restless Legs Syndrome: What Does the Evidence Say?
  • The Zoster Vaccine Rapidly Loses Effectiveness in Adults Over 60
  • Association of Traumatic Brain Injury with Late-life Neurodegenerative Diseases
  • Pharmacology Update: Oxycodone HCl and Naltrexone HCl Extended-release Capsules (Troxyca ER)
  • Clinical Briefs: Updates on the USPSTF Colorectal Cancer Screening Recommendations; SPRINT: Celebrating Benefits for Older Patients; Predicting Opioid Abuse and Dependence

Objectives

  • Describe new findings in differential diagnosis and treatment of various diseases;
  • Describe the advantages, disadvantages, and controversies surrounding the latest advances in the diagnosis and treatment of disease;
  • Identify cost-effective treatment regimens;
  • Explain the advantages and disadvantages of new disease screening procedures.

Credit Available

Physicians

  • Maximum of 2.0 AMA PRA Category 1 Credits
  • 2.0 AOA Category 2-B credits
  • 1.0 AAFP Credits
  • 2.0 ABIM MOC Credits

Sponsor

This activity is sponsored by AHC Media.

Accreditation Statement

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Physicians

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Osteopathic Association has approved this continuing education activity for up to 2.0 AOA Category 2-B credits.

Internal Medicine Alert has been reviewed and is acceptable for up to 1.0 Prescribed credit by the American Academy of Family Physicians. AAFP accreditation begins Jan. 1, 2016. Term of approval is for one year from this date with the option of yearly renewal.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty Listing

PHYSICIAN EDITOR

Stephen A. Brunton, MD

Adjunct Professor of Pharmacy Practice

College of Pharmacy

Roseman University of Health Sciences

Salt Lake City  

 

ASSOCIATE EDITORS

James Chan, PharmD, PhD

Pharmacy Quality and

Outcomes Manager, Kaiser

Permanente, Oakland, CA

 

William T. Elliott, MD, FACP

Chair, Formulary Committee

Northern California Kaiser

Permanente; Assistant Clinical

Professor of Medicine, University of California, San Francisco

 

Ellen Feldman, MD

Altru Health System
Grand Forks, ND

 

Harold L. Karpman, MD, FACC, FACP

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA

 

Louis Kuritzky, MD

Clinical Assistant Professor

University of Florida

Gainesville

 

Nitin K. Sethi, MD

Associate Professor of Neurology

Weill Cornell Medical College

 

Richard R. Watkins, MD, MS, FACP

Associate Professor of Internal Medicine
Northeast Ohio Medical University

Division of Infectious Diseases

Cleveland Clinic Akron General Medical Center

Akron, OH

 

PEER REVIEWER

Gerald Roberts, MD

Senior Attending Physician

Long Island Jewish Medical Center

NS/LIJ Health Care System
New Hyde Park, NY

 

Financial Disclosure

Internal Medicine Alert’s Physician Editor Stephen Brunton, MD, is a retained consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly, Merck, Novo Nordisk, Sanofi, and Teva; he serves on the speakers bureau of

AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Teva. Contributing Editor Louis Kuritzky, MD, is a retained consultant for AbbVie, Allergan, AstraZeneca, Janssen, Lilly, Lundbeck, Medscape, Novo Nordisk, and Sanofi Aventis; he serves on the speakers bureau of Lilly and Lundbeck. Peer Reviewer Gerald Roberts, MD; Executive Editor Leslie Coplin; and Associate Managing Editor Jonathan Springston report no financial relationships relevant to this field of study.

Drs. Karpman, Feldman, and Sethi report no financial relationships relevant to this field of study.

Dr. Watkins reports he has received research support from Actavis.

Copyright 2016, AHC Media. All rights reserved.